ALKS - Alkermes plc
21.47 0.00 (0.00%)
After hours: 4:07PM EDT
| Previous Close | 21.78 |
| Open | 21.85 |
| Bid | 21.45 x 1000 |
| Ask | 21.46 x 2200 |
| Day's Range | 21.40 - 22.18 |
| 52 Week Range | 21.29 - 46.98 |
| Volume | 599,249 |
| Avg. Volume | 1,268,790 |
| Market Cap | 3.369B |
| Beta (3Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.11 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.23 |
- Zacks•yesterday
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
CBM vs. ALKS: Which Stock Is the Better Value Option?
- Simply Wall St.•8 days ago
Did You Manage To Avoid Alkermes's (NASDAQ:ALKS) Painful 56% Share Price Drop?
Taking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Alkermes plc...
- Markit•8 days ago
See what the IHS Markit Score report has to say about Alkermes Plc.
Alkermes Plc NASDAQ/NGS:ALKSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ALKS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALKS. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALKS are favorable, with net inflows of $4.00 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•13 days ago
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
- PR Newswire•14 days ago
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune ...
- Insider Monkey•15 days ago
Here’s What Hedge Funds Think About Alkermes Plc (ALKS)
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
- Zacks•26 days ago
Biogen Reports Interim Phase III Data on Diroximel Fumarate
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
- GlobeNewswire•27 days ago
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
- Zacks•28 days ago
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
- Zacks•last month
Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•last month
Does Alkermes plc's (NASDAQ:ALKS) CEO Salary Compare Well With Others?
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011. This analysis aims first to contrast CEO...
- PR Newswire•last month
Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia -- DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT
Q1 2019 Alkermes Plc Earnings Call
- Zacks•last month
ALXN or ALKS: Which Is the Better Value Stock Right Now?
ALXN vs. ALKS: Which Stock Is the Better Value Option?
- PR Newswire•last month
Alkermes to Present at the UBS Global Healthcare Conference
DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global ...
- PR Newswire•last month
Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences
-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ...
- Motley Fool•2 months ago
Alkermes Looks Ahead to Growth
Generic competition is dragging down revenue this year, but it has FDA approvals in the wings.
Motley Fool•2 months agoAlkermes PLC (ALKS) Q1 2019 Earnings Call Transcript
ALKS earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
- Motley Fool•2 months ago
Biogen Looks to 23 Clinical Programs for Growth
First-quarter sales were up 11%, but future growth is less certain.
- Motley Fool•2 months ago
Here's Why Shares of Alkermes Sank Today
Sales of the drugmaker's schizophrenia drug Aristada disappointed investors.
